• All
  • Company Report
  • Industry Report

Biogen Inc (BIIB – Q1FY20) – Biogen look forward to grow from aducanumab in Alzheimer’s disease.

Biogen has opened BLA and has started to submit modules, expects to complete the U.S. filing for (Alzheimer’s drug) aducanumab in Q3FY20. It also initiated re-dosing study for aducanumab and higher dose study for SPINRAZA. The company entered collaboration with Sangamo Therapeutics for gene regulation therapies for neurological disease. Executive Summary Financial Statements – Income […]

Boston Scientific Corporation (BSX – Q1FY20) – Lower performance expected in coming quarters due to COVID-19.

Boston Scientific announced positive 12-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the next-generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device for patients with nonvalvular atrial fibrillation (NVAF). Presented as a late-breaking clinical trial at HRS 2020 SCIENCE, the study evaluated performance of the WATCHMAN FLX device as […]

Abbott Laboratories (ABT – Q1FY20) – Abbott’s near-term performance impacted by COVID-19.

Abbott recently launched three diagnostics tests for COVID 19, including molecular tests on its ID NOW™ rapid point of care platform and m 2000 RealTime lab based platform, and a serology blood test for the detection of the antibody, IgG, on its lab based immunoassay platforms. Organic sales growth in the quarter was led by strong […]

Global Market Performance YTD – 2019 – A dramatic performances by the stock markets

The U.S. economy grew by 1.9% in Q3FY19. There was a dip in net exports, private, fixed investments and inventories which weighed on the growth, but the consumer spending stabilized the American economy. The consumer confidence plummeted in August, post the fresh escalations to the U.S.- China trade war. There was a contraction in the […]

IMPACT INVESTING INDUSTRY – 2019 – A new wave of Social Change growing radically!

Impact investing is an exciting and rapidly growing industry powered by investors who are determined to generate social and environmental impact as well as financial returns. This is taking place all over the world, and across all asset classes. Table of Contents Executive Summary Overview Industry Analysis Result Based Financing Green Bonds Trends in 2019 […]

Medtronic plc – Double-digit growth in emerging market led to growth in FY19

Medtronic’s revenues increased by 2% to $30.56bn for FY19, which was below our guidance of $31.15bn for FY19. Revenues in Q4FY19 increased by $2mn to $8.14bn which adjusts for a $289mn negative impact from foreign currency No. of Pages – 44 Contents Executive Summary Financial Statements –Income Statement and Forecast –Balance Sheet –Cash Flow –Q4FY19 […]

AbbVie Inc (ABBV) – AbbVie showing progress in its pipeline by approval of SKYRIZI

AbbVie’s revenues declined by 1.3% to $7.83bn in Q1FY19 and increased by 0.4% operationally. The revenues declined due to a decrease in HUMIRA international revenues due to the biosimilar competition. However, HUMIRA revenues from the U.S. increased by 7.1% to $3.2bn in Q1FY19 and will not face biosimilar competition in the U.S. until FY23. Number […]

Thermo Fisher Scientific (TMO) – Acquisition of Brammer Bio will boost growth for TMO

TMO completed the acquisition of Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies, for ~$1.7bn in cash. Brammer will become part of TMO’s Pharma Services business within its Laboratory Products and Services Segment. This acquisition will boost growth for the company and therefore, we expect 4% growth in revenues in […]

Danaher Corp. (DHR) – GE Biopharma acquisition will lead to the growth in future

DHR sales grew by 4% to $4.9bn in Q1FY19 with 5.5% core revenue growth. The acquisitions increased revenues by 2.5%, while the impact of foreign currency translation decreased revenues by 4% during the quarter. Number of Pages – 39 Contents Executive Summary Financial Statements –Income Statement and Forecast –Balance Sheet –Cash Flow –Q1FY19 Results – […]

Biogen Inc (BIIB) – Strong operational performance in MS, SMA and Biosimilar Franchises

Biogen delivered strong financial results during the quarter due to the strong operational performance of the MS, SMA, and biosimilars franchises. Total revenues increased by 11% to $3.5bn and adjusted EPS increased by 15% to $6.98 for Q1FY19. Number of Pages – 47 Contents Executive Summary Financial Statements –Income Statement and Forecast –Balance Sheet –Cash […]

Abbott Laboratories (ABT) – Double-digit growth in growth drivers – FreeStyle Libre, MitraClip and Alinity

Abbott delivered strong Q1FY19 performance with 2% growth in revenues on reported basis and 7.1% growth in revenues on an organic basis. The growth was due to double-digit growth in FreeStyle Libre, MitraClip and Alinity. The adjusted EPS grew by 6.8% to $0.63 in Q1FY19 Number of pages – 41 Content: Executive Summary………………………………………………………..1 Financial Statements […]